HK Stock Market Move | CARSGEN-B (02171) increased by over 5%. The research results of CT0596 and CT1190B were presented in poster form at the EHA Annual Meeting.

date
13:50 15/06/2026
avatar
GMT Eight
Ko Xi Pharmaceutical-B (02171) rose more than 5%, up 4.86% as of the time of writing, trading at 15.75 Hong Kong dollars, with a turnover of 86.1849 million Hong Kong dollars.
CARSGEN-B (02171) rose over 5%, up 4.86% as of the time of writing, to 15.75 Hong Kong dollars, with a turnover of 86.1849 million Hong Kong dollars. On the news front, on June 15, CARSGEN-B announced that the research results of CT0596 (a universal CAR-T cell product targeting BCMA) for the treatment of relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL), as well as the research results of CT1190B (a universal CAR-T cell product targeting CD19/CD20) for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), have been presented in poster displays at the 2026 European Hematology Association (EHA) Annual Meeting.